Small molecules that inhibit notch signaling

Methods in Molecular Biology

Volumn 1187, Issue , 2014, Pages 311-322

  De Kloe, Gerdien E ^a   De Strooper, Bart ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Allosteric inhibitors; Notch; Selectivity; Transition state analogs; secretase inhibitors

Indexed keywords

BMS 906024; DEXAMETHASONE; DOCETAXEL; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; MK 0752; MRK 003; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH RECEPTOR; PF 3084014; PRESENILIN; PROTEINASE; UNCLASSIFIED DRUG; MOLECULAR LIBRARY; SECRETASE;

ALLOSTERISM; BINDING SITE; MALIGNANT NEOPLASTIC DISEASE; MOLECULE; NONHUMAN; NOTCH SIGNALING; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULAR LIBRARY; NEOPLASMS; PHARMACOLOGY;

ALLOSTERIC REGULATION; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; HUMANS; NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84925287126     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-1139-4_23     Document Type: Review

References (68)

1. Kopan R, Ilagan MX (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137:216-233
2. Hartmann D, de Strooper B, Serneels L et al (2002) The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fi broblasts. Hum Mol Genet 11:2615-2624
3. De Strooper B, Annaert W, Cupers P et al (1999) A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398:518-522
4. Struhl G, Greenwald I (1999) Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 398:522-555
5. De Strooper B (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38:9-12
6. De Strooper B, Vassar R, Golde T (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6: 99-107
7. Doody RS, Raman R, Farlow M et al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 369: 341-350
8. Wolfe MS, Xia W, Ostaszewski BL et al (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398:513-517
9. Serneels L, Van Biervliet J, Craessaerts K et al (2009) gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 324:639-642
10. Levitan D, Greenwald I (1995) Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 377:351-354
11. Shen J, Bronson RT, Chen DF et al (1997) Skeletal and CNS defects in Presenilin-1-defi cient mice. Cell 89:629-639
12. Wong PC, Zheng H, Chen H et al (1997) Presenilin 1 is required for Notch 1 and Dll1 expression in the paraxial mesoderm. Nature 387:288-292
13. Geling A, Steiner H, Willem M et al (2002) A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafi sh. EMBO Rep 3:688-694
14. Lewis HD, Pérez Revuelta BI, Nadin A et al (2003) Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages. Biochemistry 42:7580-7586
15. van Es JH, Clevers H (2005) Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol Med 11: 496-502
16. Wong GT, Manfra D, Poulet FM et al (2004) Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279:12876-12882
17. Demehri S, Turkoz A, Kopan R (2009) Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell 16:55-66
18. Groth C, Fortini ME (2012) Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin Cell Dev Biol 23:465-472
19. Li YM, Xu M, Lai MT et al (2000) Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405:689-694
20. Kreft AF, Martone R, Porte A (2009) Recent advances in the identifi cation of gammasecretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J Med Chem 52:6169-6188
21. Das C, Berezovska O, Diehl TS et al (2003) Designed helical peptides inhibit an intramembrane protease. J Am Chem Soc 125: 11794-11795
22. Bihel F, Das C, Bowman MJ et al (2004) Discovery of a subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem 47:3931-3933
23. Dovey HF, John V, Anderson JP et al (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76:173-181
24. McKee TD, Loureiro RM, Dumin JA et al (2013) An improved cell-based method for determining the γ-secretase enzyme activity against both Notch and APP substrates. J Neurosci Methods 213:14-21
25. Borgegård T, Gustavsson S, Nilsson C et al (2012) Alzheimer's disease: presenilin 2-sparing γ-Secretase inhibition is a tolerable Aβ peptidelowering strategy. J Neurosci 32:17297-17305
26. Churcher I, Ashton K, Butcher JW et al (2003) A new series of potent benzodiazepine gammasecretase inhibitors. Bioorg Med Chem Lett 13:179-183
27. Churcher I, Williams S, Kerrad S et al (2003) Design and synthesis of highly potent benzodiazepine gamma-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fl uorophenyl)-4-hydroxy-N-((3S)-1-methyl-2- oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangement. J Med Chem 46:2275-2278
28. Yang MG, Shi JL, Modi DP et al (2007) Design and synthesis of benzoazepinonederived cyclic malonamides and aminoamides as potent gamma-secretase inhibitors. Bioorg Med Chem Lett 17:3910-3915
29. Quesnelle C, Kim S-H, Lee F, et al. (2012) Bisfl uoroalkyl-1,4- benzodiazepinone compounds WO/2012/129353
30. http://clinicaltrials.gov/show/NCT01292655
31. http://clinicaltrials.gov/show/NCT01653470
32. Wei P, Walls M, Qiu M et al (2010) Evaluation of selective γ-secretase inhibitor PF-03084014 for its antitumor effi cacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 9:1618-1628
33. Zhang CC, Yan Z, Zong Q et al (2013) Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models. Stem Cells Transl Med 2:233-242
34. Mayer SC, Kreft AF, Harrison B et al (2008) Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem 51: 7348-7351
35. Krop I, Demuth T, Guthrie T et al (2012) Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 30:2307-2313
36. Chen SM, Liu JP, Zhou JX et al (2011) Suppression of the notch signaling pathway by gamma-secretase inhibitor GSI inhibits human nasopharyngeal carcinoma cell proliferation. Cancer Lett 306:76-84
37. Shi W, Harris AL (2006) Notch signaling in breast cancer and tumor angiogenesis: crosstalk and therapeutic potentials. J Mammary Gland Biol Neoplasia 11:41-52
38. Tran IT, Sandy AR, Carulli AJ et al (2013) Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest 123:1590-1604
39. Shen Y, Lv D, Wang J et al (2012) GSI-I has a better effect in inhibiting hepatocellular carcinoma cell growth than GSI-IX, GSI-X, or GSIXXI. Anticancer Drugs 23:683-690
40. Groth C, Alvord WG, Quiñones OA et al (2010) Pharmacological analysis of Drosophila melanogaster gamma-secretase with respect to differential proteolysis of Notch and APP. Mol Pharmacol 77:567-574
41. Kamstrup MR, Biskup E, Gniadecki R (2010) Notch signalling in primary cutaneous CD30+ lymphoproliferative disorders: a new therapeutic approach? Br J Dermatol 163: 781-788
42. Gu W, Xu W, Ding T et al (2012) Fringe controls naive CD4(+)T cells differentiation through modulating notch signaling in asthmatic rat models. PLoS One 7:e47288
43. Harrison H, Simões BM, Rogerson L et al (2013) Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. Breast Cancer Res 15:R21
44. Wang SF, Aoki M, Nakashima Y et al (2008) Development of Notch-dependent T-cell leukemia by deregulated Rap1 signaling. Blood 111:2878-2886
45. Pancewicz J, Taylor JM, Datta A et al (2010) Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci USA 107:16619-16624
46. Sainson RC, Aoto J, Nakatsu MN et al (2005) Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. FASEB J 19:1027-1029
47. Ota H, Katsube K, Ogawa J et al (2007) Hypoxia/Notch signaling in primary culture of rat lymphatic endothelial cells. FEBS Lett 581:5220-5226
48. Nwabo Kamdje AH, Bassi G, Pacelli L et al (2012) Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy. Blood Cancer J 2:e73
49. Joshi I, Minter LM, Telfer J et al (2009) Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood 113:1689-1698
50. van Es JH, van Gijn ME, Riccio O et al (2005) Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435:959-963
51. van Es JH, de Geest N, van de Born M et al (2010) Intestinal stem cells lacking the Math1 tumour suppressor are refractory to Notch inhibitors. Nat Commun 1:18
52. Okamoto M, Matsuda H, Joetham A et al (2009) Jagged1 on dendritic cells and Notch on CD4+ T cells initiate lung allergic responsiveness by inducing IL-4 production. J Immunol 183:2995-3003
53. Liu S, Breit S, Danckwardt S et al (2009) Downregulation of Notch signaling by gammasecretase inhibition can abrogate chemotherapyinduced apoptosis in T-ALL cell lines. Ann Hematol 88:613-621
54. Gusscott S, Kuchenbauer F, Humphries RK et al (2012) Notch-mediated repression of miR-223 contributes to IGF1R regulation in T-ALL. Leuk Res 36:905-911
55. Mizutari K, Fujioka M, Hosoya M et al (2013) Notch inhibition induces cochlear hair cell regeneration and recovery of hearing after acoustic trauma. Neuron 77:58-69
56. Curry CL, Reed LL, Golde TE et al (2005) Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 24:6333-6344
57. Pandya K, Meeke K, Clementz AG et al (2011) Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer 105:796-806
58. Okamoto R, Tsuchiya K, Nemoto Y et al (2009) Requirement of Notch activation during regeneration of the intestinal epithelia. Am J Physiol Gastrointest Liver Physiol 296:G23-G35
59. Luistro L, He W, Smith M et al (2009) Preclinical profi le of a potent gamma-secretase inhibitor targeting notch signaling with in vivo effi cacy and pharmacodynamic properties. Cancer Res 69:7672-7680
60. Debeb BG, Cohen EN, Boley K et al (2012) Pre-clinical studies of Notch signaling inhibitor RO4929097 in infl ammatory breast cancer cells. Breast Cancer Res Treat 134:495-510
61. Huynh C, Poliseno L, Segura MF et al (2011) The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS One 6:e25264
62. Osanyingbemi-Obidi J, Dobromilskaya I, Illei PB et al (2011) Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo. Mol Cancer Res 9:1746-1754
63. Sethi N, Dai X, Winter CG et al (2011) Tumorderived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19:192-205
64. Real PJ, Ferrando AA (2009) NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia 23: 1374-1377
65. DeAngelo DJ, Stone RM, Silverman LB (2006) A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 24(18S):6585
66. Real PJ, Tosello V, Palomero T et al (2009) Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 15:50-58
67. Konishi J, Kawaguchi KS, Vo H et al (2007) Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 67:8051-8057
68. Purow B (2012) Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol 727:305-319